You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Boehringer Ingelheim
Colorcon
Medtronic
Harvard Business School

Last Updated: April 5, 2020

DrugPatentWatch Database Preview

Sun Pharm Inds Inc Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for SUN PHARM INDS INC, and when can generic versions of SUN PHARM INDS INC drugs launch?

SUN PHARM INDS INC has eighty approved drugs.

There are eleven US patents protecting SUN PHARM INDS INC drugs. There is one tentative approval on SUN PHARM INDS INC drugs.

There are twenty-four patent family members on SUN PHARM INDS INC drugs in fifteen countries and one hundred and one supplementary protection certificates in sixteen countries.

Summary for Sun Pharm Inds Inc
International Patents:24
US Patents:11
Tradenames:68
Ingredients:64
NDAs:80

Drugs and US Patents for Sun Pharm Inds Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Inc AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride TABLET;ORAL 089399-001 Jul 14, 1987 AB RX No No   Start Trial   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 RX No No 8,268,804   Start Trial   Start Trial
Sun Pharm Inds Inc METOPROLOL TARTRATE metoprolol tartrate TABLET;ORAL 076670-001 Jan 15, 2004 AB RX No No   Start Trial   Start Trial
Sun Pharm Inds Inc HYDROCHLOROTHIAZIDE hydrochlorothiazide TABLET;ORAL 040810-002 Mar 27, 2007 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sun Pharm Inds Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate OINTMENT;TOPICAL 019968-001 Dec 17, 1990 4,619,921   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 5,908,838   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 5,908,838   Start Trial
Sun Pharm Inds Inc BACTRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 018374-001 Approved Prior to Jan 1, 1982 3,551,564   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SUN PHARM INDS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-01-07
➤ Subscribe Capsules 35 mg ➤ Subscribe 2015-11-25
➤ Subscribe Capsules 30 mg and 40 mg ➤ Subscribe 2012-12-31
➤ Subscribe Capsules 20 mg ➤ Subscribe 2013-06-19
➤ Subscribe Capsules 25 mg ➤ Subscribe 2016-05-16

Supplementary Protection Certificates for Sun Pharm Inds Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2217577 132019000000023 Italy   Start Trial PRODUCT NAME: ALLOPURINOLO/LESINURAD, O UN LORO SALE FARMACEUTICAMENTE ACCETTABILE O LORO SALI FARMACEUTICAMENTE ACCETTABILI(DUZALLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1300, 20180827
0503785 C300375 Netherlands   Start Trial PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
1003503 05C0048 France   Start Trial PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
2236132 92636 Luxembourg   Start Trial PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Dow
Colorcon
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.